Macular Degeneration and Stem Cells Update
On January 3, 2011, Advanced Cell Technology announced that the United States FDA approved their application to treat dry age-related macular degeneration (AMD) using retinal pigment epithelial (RPE) cells derived from human embryonic stem cells.
At the time that I wrote about this stem cell research, the location of the study had not been finalized. Jules Stein Eye Institute, UCLA School of Medicine in Los Angeles, California, United States is the study site.
All research, whether it is for macular degeneration or another disease, often starts with small beginnings. This study is no exception. There will be a total of 12 participants in this Phase I/II clinical trial. There will be 4 groups of patients. Each group will receive a different number of stem cells.
To start with the first patient will receive 50,000 cells. Then there will be a 6 week waiting period. During this time the Data Safety Monitoring Board (DSMB)will review the clinical data and recommend if the next two patients who are to get the same dose may be treated.
To find out more about this study and who is eligible to participate go to:
Macular Degeneration Stem Cell Update
Thanks so much for subscribing to Macular Degeneration News.
Leslie Degner, RN, BSN
Better Health for Better Vision